New Zealand markets open in 4 hours 18 minutes

Celyad Oncology SA (CYAD)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
3.8500-0.1400 (-3.51%)
At close: 04:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous close3.9900
Open3.9002
Bid3.6100 x 1000
Ask4.5000 x 1000
Day's range3.8200 - 3.9850
52-week range3.5300 - 9.0000
Volume11,761
Avg. volume976,741
Market cap89.816M
Beta (5Y monthly)1.32
PE ratio (TTM)N/A
EPS (TTM)-1.3540
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est12.00
  • Business Wire

    Celyad Oncology Provides Outlook for 2022

    MONT-SAINT-GUIBERT, Belgium, January 10, 2022--Regulatory News: Celyad Oncology SA (Euronext & Nasdaq: CYAD) (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced a 2021 year-end review and provided an outlook for 2022.

  • Zacks

    5 Beaten-Down Biotech Bets to Bounce Back in 2022

    Biotech stocks from the Medical sector, including APTO, CELU, CNSP, CYAD and SPRB, might be witnessing a turnaround in 2022 to emerge as solid investment options.

  • Business Wire

    Celyad Oncology SA: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

    MONT-SAINT-GUIBERT, Belgium, December 31, 2021--Regulatory News: Celyad Oncology SA (Euronext & Nasdaq: CYAD) (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, announced the below information following the issuance on 8 December 2021 of 6,500,000 new shares of Celyad Oncology SA (the "Company") to an affiliate of Fortress Investment Group (such affiliate "Fo